Clinical Trial Search

Primary: To Assess the Pharmacokinetics (Mean AM Dose) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen…

Primary: Number of Patients Who Met and Exceeded Response Criteria of Yale-Brown Obsessive-Compulsive Scale. — 0; 5 participants

Primary: Change in Lesion Size at the Completion of Antibiotic Therapy, Measured on a Continuous Scale; Change Will be Determined by Change in Diameter of the Lesions — -8.4…

Primary: Major Adverse Cardiac Event (MACE) — 85.0 Percent Probability of Freedom from MACE

Primary: Percentage of Participants Achieving Reduction From Baseline in Disease Activity Score Based on 28 Joints Count (DAS28) of More Than 1.2 Units After 24 Weeks of First…

Primary: Change in Pain Intensity — -0.8; -2.9 units on a scale

Primary: Changes From Baseline in Condition of the Peri Wound Skin — 0; 0; 5.6; 16.7 percentage of subjects

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 95.3; 80.7 percentage of participants — p=<0.001

Primary: Change in Pain Scale — 47; 48; 2; 2 participants — p=>0.999

Primary: Change From Baseline in Concentrations of Antioxidant Profile After Red Wine Intake — 22.3; 12.7 percentage of change in TAC — p=0.05

Primary: Number of Participants With Adverse Events — 40 participants

Primary: Safety Profile - Number of Subjects With at Least 1 AE — 1; 2; 3; 4 Participants

Primary: FEV1 — 0.94; 1.08; 0.95; 1.09 percentage of predicted normal values

Primary: Recanalization [Thrombolysis in Myocardial Infarction (TIMI) 2 or 3] Without Symptomatic Intracranial Hemorrhage — 60.7; 24.1 Percent of Subjects

Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Cephalexin Following a Single Dose — 38.038; 37.913…